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Abstract
Genomic rearrangements are frequently observed in cancer cells but have been difficult to
generate in a highly specific manner for functional analysis. Here we report the application of
CRISPR/Cas technology to successfully generate several types of chromosomal rearrangements
implicated as driver events in lung cancer, including the CD74-ROS1 translocation event and the
EML4-ALK and KIF5B-RET inversion events. Our results demonstrate that Cas9-induced DNA
breaks promote efficient rearrangement between pairs of targeted loci, providing a highly tractable
approach for the study of genomic rearrangements.
Introduction
Cancer cells are characterized by abnormalities in chromosome number and structure, such
as genomic rearrangements that can result in the inappropriate expression or activation of
oncogenes1. While many novel cancer-associated rearrangements continue to be identified,
it remains difficult to accurately model these events for functional analyses. The ability to
efficiently generate specific rearrangements would greatly improve our understanding of
how structural variations in the genome arise and how each of these events contributes to
disease pathogenesis.
The CRISPR/Cas system has recently been adapted to provide site-specific DNA
recognition and cleavage through a customizable RNA guide2, 3, 4, 5. Cas9 from
Streptococcus pyogenes recognizes a 20 nucleotide (nt) target sequence immediately
upstream of the requisite protospacer-adjacent motif (PAM) sequence NGG6. Co-expression
of the Cas9 enzyme and a chimeric single-guide RNA (sgRNA) results in Cas9-induced
double-strand breaks (DSBs) at the targeted genomic sequence6 (Fig. 1a). We hypothesized
that the high efficiency of DNA cleavage mediated by Cas9 would facilitate the formation of
rearrangements in a targeted manner.
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tHere we specifically investigate whether pairs of DSBs induced by RNA-guided Cas9
would be sufficient to generate chromosomal translocations and inversions (Fig. 1a). We
model several genomic rearrangements, known as driver events, in lung adenocarcinoma
which represent a variety of rearrangement types. We find that DNA cleavage by Cas9 at
two genomic loci results in detectable levels of rearrangement between the targeted regions.
DNA rearrangement also results in expression of the expected fusion transcripts and protein
products, demonstrating that CRISPR/Cas technology is a highly practical tool for the study
of genomic rearrangements.
Results
In lung adenocarcinoma, ROS1 is involved in translocations that result in in-frame fusions
with CD74 or SLC34A27, 8, 9. We first attempted to generate the CD74-ROS1
rearrangement, which arises through a translocation between CD74 on chromosome 5 and
ROS1 on chromosome 6 (Fig. 1b). We designed sgRNAs targeting intron 6 of CD74 and
intron 33 of ROS1 (Fig. 1b), which were then co-expressed with Cas9 in HEK 293T cells.
Cleavage of each targeted region was highly efficient, as assessed by the formation of indels
using the Surveyor assay (Supplementary Fig. 1a). Using primers spanning the expected
breakpoint junction, we detected translocations occurring in cells expressing both CD74 and
ROS1 sgRNAs, but not in cells expressing only a single targeting sgRNA (Fig. 1c,d).
Sequencing of breakpoints confirmed formation of the CD74-ROS1 translocation event and
we observed junction types resulting from both precise joining of predicted cleavage sites as
well as those containing short deletions that likely result from nucleolytic processing of
DNA ends during DSB repair (Supplementary Fig. 2a,b). In addition, we detected
expression of the predicted CD74-ROS1 fusion transcript from cDNA samples using primers
spanning the junction between CD74 exon 6 and ROS1 exon 33 (Fig. 1e). We were also able
to generate the same CD74-ROS1 translocation in non-transformed immortalized lung
epithelial cells (AALE)10, which represent a more relevant cellular context for studying the
CD74-ROS1 rearrangement event (Supplementary Fig. 3). Collectively, these results
demonstrate that Cas9-induced DSBs are sufficient to promote translocations between
targeted chromosomes in multiple cell types.
Next, we sought to determine whether Cas9-mediated DNA cleavage could promote the
formation of intrachromosomal inversions. We chose to model the EML4-ALK and KIF5B-
RET rearrangements observed in lung cancer, which represent two different types of
inversion events. EML4-ALK is the result of a paracentric inversion of chromosome 2p11,
while KIF5BRET is the result of a pericentric inversion across the two arms of chromosome
109, 12, 13, 14 (Fig. 2a,f). We first selected target sites that were in the immediate vicinity of
intronic breakpoints identified in patient samples containing the EML4-ALK11 and KIF5B-
RET13 rearrangements. Introduction of constructs expressing Cas9 and each targeting
sgRNA into HEK 293T cells resulted in efficient site-specific cleavage, as detected by indel
formation (Supplementary Fig. 1b,c). For both EML4-ALK and KIF5B-RET, the expected
inversions were only detected in cells expressing Cas9 along with the appropriate pair of
sgRNAs, as compared to controls cells expressing only one sgRNA (Fig. 2 b,g). EML4-ALK
and KIF5B-RET fusion transcripts were also detected only when both sites were targeted
(Fig. 2 c,h), and matched the predicted sequence (Fig. 2 d,i; Supplementary Figure 4). In
Choi and Meyerson Page 2
Nat Commun. Author manuscript; available in PMC 2014 October 24.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
taddition, among single-cell clones that were derived from cells transfected with the
combination of EML4 and ALK sgRNAs, we identified several positive clones that
expressed the EML4-ALK fusion protein (Fig. 2e).
To estimate the efficiency of the induced EML4-ALK and KIF5B-RET rearrangements, we
developed a flow cytometric assay to quantify ALK or RET protein expression at the single-
cell level. Untreated HEK 293T cells do not express appreciable amounts of either ALK or
RET, allowing the levels of these proteins to serve as surrogate markers of successful
rearrangement. For the EML4-ALK rearrangement, we observed increased ALK expression
in approximately 8% of cells treated with both EML4 and ALK sgRNAs, compared to 1% or
less of cells treated with single sgRNAs or no sgRNAs (Fig. 3a), while for the KIF5B-RET
rearrangement, we observed increased RET expression in approximately 1.6% of cells
treated with both KIF5B and RET sgRNAs, compared to less than 0.5% of cells treated with
single sgRNAs or no sgRNAs (Fig. 3b). Taken together, our results demonstrate that
intrachromosomal inversions involving a single arm or occurring across both arms can be
readily generated using the CRISPR/Cas system.
Discussion
We have found that targeted DNA DSBs induced by Cas9 can promote genomic
rearrangements of several types, including interchromosomal translocations and
intrachromosomal inversions. Previously, it has been reported that chromosomal
rearrangements can also be generated using meganucleases, zinc-finger nucleases (ZFNs)
and transcription activator-like effector nucleases (TALENs)15, 16, 17. While all of these
tools have revolutionized our ability to manipulate the genome, the CRISPR/Cas9 system
offers several unique advantages. The ease with which sgRNAs can be designed and cloned
makes the CRISPR system well-suited for high-throughput screening experiments. Also, the
ability to multiplex Cas9 targeting opens up the possibility of studying more complex
combinations of rearrangements observed in cancer genomes, such as those resulting from
chromothripsis18 or chromoplexy19. In addition, while off-target recognition and cleavage
by Cas9 may result in non-specific chromosomal rearrangements, these unintended effects
could be minimized by generating DSBs using a ‘double-nicking’ strategy20, 21 or targeting
with shorter 17nt sgRNAs which exhibit greater specificity22.
The rearrangements and inversions induced in this study are most likely occurring through
the non-homologous end-joining (NHEJ) pathway of DSB repair, as they involve the joining
of mismatched ends. We did not detect regions of significant homology between the targeted
DNA regions, suggesting that alternative forms of repair, such as non-allelic homologous
recombination (NAHR) are unlikely to be responsible for generating the induced
rearrangements. From our analysis of the rearranged genomic breakpoint junctions, we
observed a high frequency of exact fusion events, which may be explained by the
mechanism of Cas9-mediated DNA cleavage. It has been described previously that Cas9
generates blunt ends precisely three base-pairs upstream of the PAM sequence6. Since the
resulting blunt DNA ends would not require further end-processing prior to ligation in the
NHEJ pathway of repair, rearrangements between Cas9-generated ends may frequently
occur as exact fusion events. Similarly, NHEJ-mediated repair of blunt-ended signal joints
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tgenerated during V(D)J recombination also results in precise error-free fusions23. However,
the nature of an induced fusion site is also likely to depend on a variety of other factors, such
as features specific to the genomic regions that are targeted, the unique properties of the cell
lines that are used, and the levels of Cas9/sgRNAs that are expressed.
We propose that Cas9-mediated targeting of endogenous loci provides a highly useful
approach for the study of novel chromosomal rearrangements and their functional
significance in human disease. Accurate modeling of rearrangements will provide
opportunities to not only study the phenotypic consequences of specific events, but to also
investigate the mechanisms that contribute to structural changes to the genome.
Methods
CRISPR sgRNA target selection and cloning
Suitable sgRNA target sites were manually identified based on the following criteria: an
initiating G on the 5′ end, the presence of an NGG motif on the 3′ end, proximity to
breakpoints previously reported in patient samples (when such information was available),
and sequence uniqueness by BLAST search. Oligos encoding the targeting sequence were
then annealed and ligated into the BbsI sites of pX3303 (Addgene #42230).
Cell transfection and DNA extraction
HEK 293T cells were plated the day prior to transfection at 106 cells per well of a 6-well
plate. On the day of transfection, the media was replaced to antibiotic-free DMEM/10%
FBS. Cells were treated with 25μM of chloroquine and transfected with a total of 2μg of
DNA by the calcium phosphate method (CalPhos Kit, Clontech #631312). Transfection
efficiencies were estimated by transfection of a GFP reporter plasmid in each experiment
and averaged 85-95%.
For transfection of AALE cells, 5 × 105 cells were nucleofected with a total of 2μg of DNA
of DNA using the Basic Epithelial Cell Nucleofector Kit (Lonza VPI-1005) and the T13
setting. Media was replaced the following day and cells were harvested approximately 72hrs
post-transfection. DNA was extracted from cells using Quickextract DNA extraction
solution (Epicentre #QE09050) and diluted to 10ng μl−1 for subsequent PCR analyses.
RNA extraction and RT-PCR
Total RNA was purified from cells using the NucleoSpin RNA kit (Machery-Nagel
#740955). First-strand cDNA synthesis was subsequently carried out on 1μg of total RNA
with the iScript cDNA Synthesis Kit (Bio-Rad #170-8891).
PCR-based detection of genomic breakpoints and cDNA fusions
PCR amplification was carried out using Q5 high-fidelity DNA polymerase (NEB #M0491).
PCR products were electrophoresed on 2% TBE gels and purified using the Nucleospin Gel
and PCR Clean-up kit (Machery-Nagel #740609). Purified PCR products were directly
sequenced using the forward PCR primer. CD74-ROS1 and ROS1-CD74 genomic
breakpoint PCR products were cloned into pJET1.2 using the CloneJET PCR Cloning Kit
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t(Thermo Scientific #K1231) and individual clones were sequenced. PCR primers are listed
in Supplementary Table 1.
Isolation of EML4-ALK clones and western blotting
HEK 293T cells transfected with both EML4 and ALK sgRNAs were single cell cloned by
limiting dilution in 96-well plates. Individual clones were screened by PCR for the EML4-
ALK genomic rearrangement. PCR-positive clones were subsequently screened by western
blotting for ALK expression using standard procedures. Cells were lysed in RIPA buffer and
lysates were separated on 4-12% Bis-Tris NuPage gels (Invitrogen). After transferring to
PVDF membranes, blots were probed with antibodies against ALK (Cell Signaling #3633,
1:1000) or ACTB (Cell Signaling #8457, 1:1000).
Surveyor nuclease assay
Genomic regions surrounding sgRNA-targeted sites were amplified by PCR (see
Supplementary Table 1 for primer sequences). PCR products were gel-extracted or purified
directly using the Nucleospin Gel and PCR Clean-Up Kit (Machery-Nagel, #740609).
Approximately 200-400 ng of each PCR product was then denatured and re-annealed in 20μl
total volume containing Pfu Turbo reaction buffer, as specified in the Surveyor Mutation
Detection Kit protocol (Transgenomics #706020). Next, 2μl of 0.15M MgCl2, 1μl of
Surveyor enhancer solution, and 1μl of Surveyor nuclease was added and the mixture was
incubated at 42C for 60min. Reactions were stopped with addition of 2μl of Stop solution
and separated on 2% TBE agarose gels.
Intracellular staining for ALK and RET
Cells were washed in PBS and fixed with 2% paraformaldehyde in PBS for 10 min. at 37°C.
After washing in PBS, cells were permeabilized in cold 90% methanol for 30 min. on ice.
Cells were then washed in 0.5% BSA in PBS and stained with anti-ALK (Cell Signaling
Technology, #3633P, 1:400) or anti-RET (Cell Signaling Technology, #3223S, 1:50) for 1
hour at room temperature, followed by a wash in 0.5% BSA in PBS, and staining with anti-
rabbit Alexa Fluor 488 secondary antibody (Life Technologies, #A11070, 1:500) for 30 min
at room temperature. After a final wash, cells were resuspended in PBS and analyzed on a
BD LSR Fortessa flow cytometer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Cas9-induced DNA breaks promote interchromosomal translocations
a) Schematic depicting the overall strategy for generating chromosomal rearrangements.
Cas9 from S.pyogenes (SpCas9) is co-expressed with two single-guide RNAs (sgRNA 1 and
2) which direct DNA cleavage at each targeted genomic site. b) The CD74-ROS1
rearrangement results from a translocation between chromosomes 5 and 6. Shown are the
intronic sites where Cas9 was targeted. c-d) PCR detection of the c) CD74-ROS1 Der(6) and
d) ROS1-CD74 Der(5) genomic breakpoint junctions from HEK 293T cells in which Cas9
was expressed with no sgRNA (vector), CD74 sgRNA alone, ROS1 sgRNA alone, or both
CD74 and ROS1 sgRNAs. e) Sequence chromatogram of the detected CD74-ROS1 fusion
transcript from cells in which Cas9 and both CD74 and ROS1 sgRNAs were expressed. Data
shown are representative results from a total of three independent experiments.
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tFigure 2. Cas9 can be targeted to generate paracentric and pericentric intrachromosomal
inversions
a) The EML4-ALK rearrangement results from a paracentric inversion in chromosome 2.
Shown are the intronic sites where Cas9 was targeted. b-c) PCR detection of the EML4-ALK
b) genomic breakpoint junction and c) fusion transcript from HEK 293T cells in which Cas9
was expressed with no sgRNA (vector), EML4 sgRNA alone, ALK sgRNA alone, or both
EML4 and ALK sgRNAs. d) Sequence chromatogram of the detected EML4-ALK fusion
transcript from cells in which Cas9 and both EML4 and ALK sgRNAs were expressed. e)
Western blot for EML4-ALK protein expression in single clones of 293T cells which were
untreated, or in which Cas9 and both EML4 and ALK sgRNAs were expressed. NCIH3122
cells are shown as a positive control. f) The KIF5B-RET rearrangement results from a
pericentric inversion in chromosome 10. Shown are the intronic sites where Cas9 was
targeted. g-h) PCR detection of the KIF5B-RET g) genomic breakpoint junction and h)
fusion transcript from HEK 293T cells in which Cas9 was expressed with no sgRNA
(vector), KIF5B sgRNA alone, RET sgRNA alone, or both KIF5B and RET sgRNAs. i)
Sequence chromatogram of the detected KIF5B-RET fusion transcript from cells in which
Cas9 and both KIF5B and RET sgRNAs were expressed. Data shown are representative
results from a total of three independent experiments.
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tFigure 3. Estimated efficiencies of inducing EML4-ALK and KIF5B-RET rearrangements
HEK 293T cells transfected with Cas9 and no sgRNA (Vector), a single sgRNA, or a pair of
sgRNAs were stained for either (a) ALK or (b) RET protein to estimate the percentage of
cells with induced EML4-ALK or KIF5B-RET rearrangements, respectively. All values
represent means of at least 3 independent experiments +/− s.e.m. Means were compared by
paired t-test (**p<0.01, ***p<0.001). Also shown are dotplots from a representative
experiment for each rearrangement.
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